Pure Global
NCT06277219

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Latticon Antibody Therapeutics, Inc·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
LAT010
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Latticon Antibody Therapeutics, Inc
Location
Salt Lake City, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Mar 01, 2024
End date
Mar 01, 2027
Enrollment
150 participants
Primary outcome

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1),Incidence of changes in clinical laboratory values (Phase 1),Incidence of dose-limiting toxicities (DLTs) (Phase 1),Objective response rate (ORR) per RECIST 1.1 (Phase 2)

Summary

This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and
 cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK,
 PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2
 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06277219
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06277219 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Latticon Antibody Therapeutics, Inc and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.